{"id":66234,"date":"2019-12-30T23:55:42","date_gmt":"2019-12-31T04:55:42","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/la-fda-ha-concesso-la-designazione-breakthrough\/"},"modified":"2019-12-30T23:55:42","modified_gmt":"2019-12-31T04:55:42","slug":"la-fda-ha-concesso-la-designazione-breakthrough","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/it\/la-fda-ha-concesso-la-designazione-breakthrough\/","title":{"rendered":"La FDA ha concesso la designazione Breakthrough"},"content":{"rendered":"<p>La Food and Drug Administration statunitense ha concesso la Breakthrough Therapy Designation a cobimetinib per il trattamento di pazienti affetti da neoplasie istiocitiche (Erdheim-Chester Malattia di Rosai-Dorfman, Istiocitosi di Langerhans) che non presentano la mutazione <em>BRAF<\/em> V600. Questo non \u00e8 solo un grande passo avanti per i pazienti <em>BRAF-negativi<\/em> di ECD, ma per tutte le istiocitosi. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Food and Drug Administration statunitense ha concesso la Breakthrough Therapy Designation a cobimetinib per il trattamento di pazienti affetti da neoplasie istiocitiche (Erdheim-Chester Malattia di Rosai-Dorfman, Istiocitosi di Langerhans) [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":91088,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_wds_title":"","_wds_metadesc":"","_wds_focus-keywords":"","_wds_meta-robots-adv":"","_wds_meta-robots-noindex":false,"_wds_meta-robots-nofollow":false,"_wds_meta-robots-index":false,"_wds_meta-robots-follow":false,"_wds_autolinks-exclude":false,"_wds_canonical":"","_wds_redirect":"","_wds_opengraph":[],"_wds_twitter":[],"cybocfi_hide_featured_image":"","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2079],"tags":[2125],"class_list":["post-66234","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-comunicati-stampa","tag-2019-it"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/posts\/66234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/comments?post=66234"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/posts\/66234\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/media\/91088"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/media?parent=66234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/categories?post=66234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/it\/wp-json\/wp\/v2\/tags?post=66234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}